SEP 22, 2015 09:00 AM PDT
WEBINAR: Galectin-3 A Step Towards a Clearer Pathway in Heart Failure Management
9 39 11115

  • Consultant Cardiologist and Vice Chief of Medicine, Baylor University Medical Center
      After receiving a bachelor's degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School in Dallas. He went on to complete his internal medicine residency at the University of Washington in Seattle, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master's degree in public health at the University of Michigan. Dr. McCullough directs cardiovascular education and research for the Baylor Health Care System and is a Vice Chief of Medicine at Baylor University Medical Center in Dallas, TX and is a Principal Faculty in internal medicine for the Texas A & M University Health Sciences Center. He is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with over 1000 publications including the "Interface between Renal Disease and Cardiovascular Illness" in Braunwald's Heart Disease Textbook. In 2013, he was honored with the International Vicenza Award for Critical Care Nephrology for his outstanding contribution and dedication to the emerging problem of cardiorenal syndromes. Dr. McCullough is the current Chair of the National Kidney Foundation's Kidney Early Evaluation Program (KEEP), the nation's largest community screening effort for chronic diseases. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, and other top-tier journals worldwide. He is the co-editor of Reviews in Cardiovascular Medicine and serves on the editorial boards of multiple specialty journals.

      Major Contributions:

      • Senior leadership and oversight of clinical, education, and research operations at major academic medical centers

      • Clinical development of in vitro diagnostic assays for heart and kidney disease now used worldwide

      • Editor and Chairman, KEEP Annual Data Report published in the American Journal of Kidney Disease

      • Observational studies and randomized trials of therapies for acute kidney injury, hypertension, acute coronary syndromes, heart failure, and cardiorenal syndromes

      • Board certification in internal medicine, cardiology, clinical lipidology, and echocardiography with a practice dedicated to the prevention and treatment of common diseases including obesity, diabetes, kidney and heart disease

    DATE: Sept 22, 2015
    TIME: 9:00am PDT, 12:00PM EDT

    Heart failure is a complex syndrome and affects over 5.1 Million Americans today with approximately 500,000 new heart failure cases each year. Heart failure is the leading cause of emergency room visits, hospitalizations, and death for Americans today. Although, there have been significant advances in heart failure diagnosis, management, and treatment there is still a need for new tools to help optimize the management of this healthcare burden. Recently, novel biomarkers have emerged as additional tools to aid in prognosis and management of heart failure. During today's webcast, we will learn about a new and emerging biomarker called galectin-3 and how it can be used as a management tool for heart failure patients in the US.

    Learning Objectives:
    • Understand what is galectin-3
    • Learn about pathophysiology of cardiac fibrosis and the role of galectin-3
    • Comprehend how galectin-3 can used as a management tool for heart failure patients

    Who Should Attend:
    • Laboratorians
    • Heart failure nurses
    • Heart failure specialists
    • Cardiologists
    • Emergency Physicians

    Show Resources
    Loading Comments...